Singapore becomes first market in Southeast Asia to launch BESREMi ®️ , setting a new standard for rare disease care Redefining Polycythaemia Vera (PV) care, BESREMi® is the only therapy approved by Singapore's Health Sciences Authority (HSA) for adults with PV, regardless of treatment history SINGAPORE , Sept. 9, 2024 /PRNewswire/ -- PharmaEssentia Corporation (TWSE:6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in haematology and oncology, proudly announces the availability of BESREMi® (ropeginterferon alfa-2b) in Singapore. The country is the first market in Southeast Asia to introduce this breakthrough therapy for Polycythaemia Vera (PV).
The launch coincides with MPN (Myeloproliferative Neoplasms) Awareness Day on 12 September, highlighting PharmaEssentia's commitment to addressing unmet medical needs and advancing patient outcomes. Advancing PV Treatment and Awareness Polycythaemia Vera (PV) is a rare blood cancer characterised by the abnormal and uncontrolled growth of blood cells in the bone marrow. There are around 500 PV patients in Singapore and another 5,000 patients across the rest of Southeast Asia .
The low level of awareness around PV complicates effective disease management, making MPN Awareness Day crucial for educating the public and healthcare professionals about PV, its impact, the importance of early detection, diagnosis and treatment. Dr. Peggy Loh , Singapore General .